At WIRED's Big Interview event, Eli Lilly and Company's Executive Vice President and Chief Information and Digital Officer, ...

Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

US pharma major Eli Lilly (NYSE: LLY) has reported positive topline data from its Phase III ATTAIN-MAINTAIN trial, showing that its oral GLP-1 candidate orforglipron helped patients maintain weight ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Fosun is joining the fray through its subsidiary Yao Pharma, which has granted Pfizer an exclusive worldwide license to ...

The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...

The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...

U.S. Olympians Elana Meyers Taylor and Gabby Thomas participated in a social video, drawing a throughline between their ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...